Soluble epoxide hydrolase: A potential target for metabolic diseases
- PMID: 26621325
- DOI: 10.1111/1753-0407.12358
Soluble epoxide hydrolase: A potential target for metabolic diseases
Abstract
Epoxyeicosatrienoic acids (EETs), important lipid mediators derived from arachidonic acid, have many beneficial effects in metabolic diseases, including atherosclerosis, hypertension, cardiac hypertrophy, diabetes, non-alcoholic fatty liver disease, and kidney disease. Epoxyeicosatrienoic acids can be further hydrolyzed to less active diols by the enzyme soluble epoxide hydrolase (sEH). Increasing evidence suggests that inhibition of sEH increases levels of EETs, which have anti-inflammatory effects and can prevent the development of hypertension, atherosclerosis, heart failure, fatty liver, and multiple organ fibrosis. Arachidonic acid is the most abundant omega-6 polyunsaturated fatty acid (PUFA) and shares the same set of enzymes with omega-3 PUFAs, such as docosahexaenoic acid and eicosapentaenoic acid. The omega-3 PUFAs and metabolites, such as regioisomeric epoxyeicosatetraenoic acids and epoxydocosapentaenoic acids, have been reported to have strong vasodilatory and anti-inflammatory effects. Therefore, sEH may be a potential therapeutic target for metabolic disorders. In this review, we focus on our and other recent studies of the functions of sEH, including the effects of its eicosanoid products from both omega-3 and omega-6 PUFAs, in various metabolic diseases. We also discuss the possible cellular and molecular mechanisms underlying the regulation of sEH.
Keywords: arachidonic acid; epoxyeicosatrienoic acids; metabolic disease; polyunsaturated fatty acids; soluble epoxide hydrolase; 代谢性疾病; 可溶性表氧化物水解酶; 多不饱和脂肪酸; 环氧-二十碳三烯酸; 花生四烯酸.
© 2015 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Similar articles
-
Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides.Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):536-41. doi: 10.1073/pnas.1422590112. Epub 2014 Dec 30. Proc Natl Acad Sci U S A. 2015. PMID: 25550510 Free PMC article.
-
Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.J Cardiovasc Pharmacol. 2013 Sep;62(3):285-97. doi: 10.1097/FJC.0b013e318298e460. J Cardiovasc Pharmacol. 2013. PMID: 23676336 Free PMC article.
-
The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling.Vascul Pharmacol. 2016 Nov;86:31-40. doi: 10.1016/j.vph.2016.03.001. Epub 2016 Mar 11. Vascul Pharmacol. 2016. PMID: 26975734 Review.
-
Lipid mediators generated by the cytochrome P450-Epoxide hydrolase pathway.Adv Pharmacol. 2023;97:327-373. doi: 10.1016/bs.apha.2022.12.004. Epub 2023 Jan 19. Adv Pharmacol. 2023. PMID: 37236763 Review.
-
Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.Pharmacol Ther. 2022 Dec;240:108213. doi: 10.1016/j.pharmthera.2022.108213. Epub 2022 May 18. Pharmacol Ther. 2022. PMID: 35597366 Review.
Cited by
-
Salt-sensitive hypertension in GR mutant rats is associated with altered plasma polyunsaturated fatty acid levels and aortic vascular reactivity.Pflugers Arch. 2024 Sep 10. doi: 10.1007/s00424-024-03014-y. Online ahead of print. Pflugers Arch. 2024. PMID: 39256246
-
Essential Oils of Laurus nobilis L.: From Chemical Analysis to In Silico Investigation of Anti-Inflammatory Activity by Soluble Epoxide Hydrolase (sEH) Inhibition.Foods. 2024 Jul 20;13(14):2282. doi: 10.3390/foods13142282. Foods. 2024. PMID: 39063366 Free PMC article.
-
The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids.Front Pharmacol. 2024 Apr 2;15:1358256. doi: 10.3389/fphar.2024.1358256. eCollection 2024. Front Pharmacol. 2024. PMID: 38628644 Free PMC article. Review.
-
Regulation of soluble epoxide hydrolase in renal-associated diseases: insights from potential mechanisms to clinical researches.Front Endocrinol (Lausanne). 2024 Feb 15;15:1304547. doi: 10.3389/fendo.2024.1304547. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38425758 Free PMC article. Review.
-
Crosstalk between proximal tubular epithelial cells and other interstitial cells in tubulointerstitial fibrosis after renal injury.Front Endocrinol (Lausanne). 2024 Jan 8;14:1256375. doi: 10.3389/fendo.2023.1256375. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260142 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical